Medical Software Development: Architecture & SaMD.

A healthtech CTO faces a regulatory maze. In the clinical space, compliance requirements do not simply sit alongside technical choices but actively dictate them. Developing custom applications in this sector requires an architecture built around safety, accountability, and traceability from the very first line of code.

For teams building clinical platforms, the decision to build or buy represents a critical inflection point. Shifting frameworks across the UK and Europe, which we address during our initial medical software discovery sessions, further complicate this choice. Standard frameworks like UK MDR 2002 and EU MDR 2017/745 dictate precise engineering controls for every component.

Navigating this landscape demands a deep understanding of standard software lifecycles, particularly the structured engineering requirements of IEC 62304. We detail our work in this space further in our overview of health tech app development in the UK, which outlines practical pathways for clinical systems. This paper examines how technical decision-makers can navigate these regulatory hurdles while delivering robust, scalable architectures.

This guide provides a comprehensive, evidence-first analysis of medical software design, covering cloud-native deployment, interoperability standards, and clinical safety. We explore how to manage legacy system integrations, isolate third-party dependencies, and navigate the technical realities of modern healthcare deployment. The following sections equip clinical software engineers with the exact frameworks needed to build compliant, high-performing systems.

Key Findings at a Glance

• Regulatory classifications under UK MDR 2002 and EU MDR Rule 11 trigger a Class IIa minimum for software with diagnostic or therapeutic functions, with transition timelines extended through 2030 [1]. These classification paths mandate rigorous compliance architectures across both cloud environments and mobile solutions [2, 5, 8].
• Cloud-native medical software must reconcile NHS England Cloud First policies and Data Security and Protection Toolkit specifications with the strict traceability obligations of IEC 62304 [2]. This requires engineering teams to implement distinct architectural boundaries that isolate clinical algorithms from general system infrastructure, protecting proprietary data and mitigating software of unknown provenance risks [5, 6].
• While HL7 FHIR R4 is the primary interoperability standard, persistent semantic gaps across EHR platforms like Epic, EMIS, and TPP SystmOne present significant integration friction [3]. CTOs must design api-first layers to counter structural vendor lock-in, treating data portability and interoperability as core architectural foundations rather than post-development features [7, 10].
• Machine learning lifecycles fall outside traditional IEC 62304 guidelines, introducing a regulatory mismatch that healthtech developers must address using Predetermined Change Control Plans and joint international frameworks [4]. Technical leads must establish automated model drift validation and clinical safety assessments early in the development lifecycle to secure market access [9, 10].

Introduction

A healthtech CTO faces a regulatory maze. The wrong architecture can sink a product before it launches. The medical software development landscape presents a layered challenge that does not simplify with familiarity.

Regulatory frameworks (UK MDR 2002, EU MDR 2017/745, IEC 62304, and the IMDRF SaMD classification framework) interact with architectural constraints, interoperability standards, and AI and ML integration considerations. These interactions make isolated decisions systematically connected.

A CTO who resolves the regulatory classification question correctly but underweights the interoperability architecture will build software that passes submission and fails in deployment. This architectural imbalance often leads to expensive post-launch refactoring cycles that stall commercial growth. Early alignment across these domains is therefore a baseline engineering requirement.

This paper examines what the evidence shows about medical software architecture, the build-versus-buy decision, and the technical factors that determine engineering success. It is written specifically for technical decision-makers and founders navigating healthtech in the UK and Europe. The goal is to provide an objective, decision-ready framework grounded in documented regulatory and technical standards.

The paper proceeds systematically through ten technical sections. Each part unpacks a specific layer of the clinical engineering and compliance challenge.

Section 1 opens with the regulatory landscape and the frameworks governing certification decisions. Section 2 then examines core architectural patterns, cloud-native deployment, and NHS data sovereignty constraints. Section 3 addresses the clinical interoperability challenge, highlighting why system integration remains a dominant failure mode.

Section 4 covers emerging AI and machine learning integration, analysing current gaps in regulatory oversight. Section 5 details the Software as a Medical Device (SaMD) classification framework alongside its direct engineering implications. Section 6 provides a technical analysis of the build-versus-buy decision, specifically relating to legacy Electronic Health Record (EHR) integration.

Section 7 expands on EHR platform evaluation, focusing on vendor selection and true data portability. Section 8 addresses the mobile question for clinical applications, comparing native and cross-platform architectures. Section 9 maps how healthtech decision-makers navigate procurement, while Section 10 outlines three structural non-negotiables for software delivery.

The stakes for technical leadership are exceptionally high. A single regulatory miscalculation or architectural oversight can render an otherwise functional clinical system completely unusable.

Software that receives regulatory certification but fails to integrate with clinical workflows is software that clinicians abandon. This misalignment creates immediate operational friction and wastes critical capital. Engineers must design with both regulatory compliance and end-user clinical utility in mind.

Conversely, software that is architecturally sound but built without clear IEC 62304 traceability is software that fails regulatory submission. Reconstructing technical documentation retrospectively is often more expensive than starting the code base from scratch. Technical leaders must embed compliance constraints directly into the initial git repository setup.

Similarly, software that navigates approval and interoperability but neglects AI and machine learning frameworks hits an absolute regulatory wall at deployment. This roadblock typically occurs when trying to run unvalidated clinical decision support algorithms in live clinical environments. This paper examines all three failure modes to provide technical teams with the empirical evidence needed to avoid them.

1. The Regulatory Landscape

Whether software used in healthcare requires medical device certification is not a binary question. It is a layered determination governed by multiple, overlapping regulatory frameworks. For a technical director evaluating compliance pathways, understanding the interaction between UK, EU, and international regulatory instruments is foundational, as subsequent architectural choices rely entirely on this framework.

The UK MDR 2002 and Post-Brexit Trajectory

The Medical Devices Regulations 2002 (SI 2002/618, as amended) constitute the primary UK legal instrument governing medical devices. These regulations originally transposed the EU Medical Devices Directive (93/42/EEC) into domestic law before Brexit. Following the UK's departure from the EU, the Medicines and Healthcare products Regulatory Agency has progressively diverged from the European regulatory framework.

Under current transitional arrangements, CE certificates issued under the EU MDR remain valid in Great Britain until 30th June 2030. This extended timeline offers healthtech developers a dual-market window. The MHRA has introduced its own software qualification guidance, distinguishing between Medical Device Software and general wellness applications.

Software qualifies as a medical device under UK MDR 2002 if it has a specific medical purpose as defined in the regulations. This threshold encompasses clinical decision support, diagnosis, monitoring, and treatment assistance functions [2]. For manufacturers, UK market access requires either a UKCA mark or reliance on CE marking until the 2030 transition deadline.

Securing a UKCA mark requires successful completion of the MHRA type examination and conformity assessment. The regulator's software-specific guidance clarifies that standalone software performing a medical function requires certification. This obligation applies to any algorithms processing patient data to generate clinical recommendations, regardless of whether they execute on general-purpose hardware or within a clinical system [13].

EU MDR 2017/745: The Classification Engine

The EU Medical Device Regulation (MDR 2017/745), which became fully applicable in May 2021, establishes stringent safety requirements. This legislation represents the most comprehensive shift in European medical device regulation in decades. For Software as a Medical Device, the MDR introduces explicit qualification criteria and classification rules that directly determine the burden of conformity assessment [17].

Under MDR Rule 11, software intended to provide information used to make decisions with diagnostic or therapeutic purposes is classified as Class IIa at a minimum. This classification encompasses algorithms, neural networks, and rule-based systems. The rule escalates the software to Class IIb or Class III if the decisions could cause death or irreversible deterioration of health.

Achieving Class IIa compliance under Rule 11 necessitates rigorous engineering verification and validation. This includes demonstrating software integrity through comprehensive stress testing, hazard analyses, and clinical evaluation reports reviewed by an independent Notified Body. Manufacturers must also establish a formal Quality Management System and implement a post-market surveillance plan proportionate to the risk profile [7].

Research examining MDR implications for artificial intelligence indicates that Rule 11 captures the vast majority of clinical decision support systems. Consequently, the boundary cases between software providing passive background analytics and platforms delivering actionable recommendations require careful technical interpretation [7]. This distinction dictates whether an engineering team must prepare extensive conformity documentation.

IEC 62304: The Software Lifecycle Standard

IEC 62304:2006 is the international standard establishing lifecycle requirements for medical device software development and maintenance. Though not a statutory law itself, regulatory frameworks across the UK, EU, and United States reference it as the default engineering expectation. Consequently, demonstrating compliance with this standard is effectively mandatory for seeking market authorisation [2].

The standard assigns software a safety classification based on its contribution to potential hazardous situations. This classification determines the depth of engineering evidence required during regulatory audits. The framework defines three safety tiers, spanning Class A for no risk, Class B for non-serious injury, and Class C where death or serious injury is possible.

This safety classification directly drives the rigour of software verification and validation activities. Class C software demands detailed architectural designs, comprehensive regression testing plans, and explicit acceptance criteria. Industry practitioner discussions confirm that gathering this technical documentation accounts for a substantial proportion of regulatory submission delays [13].

Estimates suggest incomplete or poorly structured lifecycle documentation contributes to the majority of compliance setbacks. To prevent these delays, engineering teams must integrate compliance verification directly into their daily continuous integration pipelines rather than treating it as a final step.

IEC 62304 integrates tightly with ISO 14971:2019, the international risk management standard. This standard defines the process for identifying hazards, estimating associated risks, and implementing systematic risk controls throughout the lifecycle. Both frameworks are referenced explicitly in the EU MDR's General Safety and Performance Requirements under Annex I [17].

This explicit integration establishes both standards as de-facto obligations for developers targeting European certification. Failing to align risk management with software development processes represents a fundamental failure in technical compliance.

SaMD Classification: The IMDRF Framework

The International Medical Device Regulators Forum published its SaMD risk categorisation framework in 2014. This established a four-category system, spanning Roman numerals I to IV, based on two primary variables. These variables evaluate the significance of the information provided to the healthcare decision and the criticality of the underlying clinical condition [17].

This harmonised framework has been adopted in varying degrees by the FDA, Health Canada, and European regulators. It provides a consistent vocabulary for classifying software according to clinical risk rather than platform architecture.

Under this framework, software providing information to healthcare professionals to support clinical decisions occupies a different category than patient-facing self-management applications. This remains true even when the underlying clinical algorithm is identical. The resulting classification determines both the intensity of pre-market evaluation and the evidence expectations for post-market clinical performance.

The Practical Compliance Question

For a technical lead evaluating whether their software requires medical device certification, the threshold question centres on medical intent. Functions triggering certification include diagnosis, monitoring, treatment, prevention, or the alleviation of disease. These clinical functions contrast sharply with administrative, logistical, or general wellness applications [4].

The EU MDR guidance on software qualification establishes that platforms processing patient data to generate clinical recommendations fall within scope. The MHRA applies equivalent logic under the UK MDR 2002. In both jurisdictions, the legal burden falls entirely on the manufacturer to justify their qualification determination.

The consequences of an incorrect self-assessment are severe, ranging from immediate market withdrawal to recalls and civil liability [17]. Engineering teams must therefore document their qualification rationale in a formal technical file before writing initial code.

Cybersecurity requirements introduce an additional, non-negotiable layer of engineering overhead. For example, the FDA now mandates robust penetration testing and software bills of materials for new device submissions. Similarly, the EU MDR general safety requirements encompass cyber resilience as part of the obligation to minimise IT risks [17].

The joint guiding principles on machine learning from the FDA, Health Canada, and the MHRA increasingly shape global expectations for software transparency. These standards mandate formal threat modelling, secure update pathways, and strict vulnerability management throughout the active lifecycle.

What This Means Architecturally

The regulatory landscape outlined above represents a set of hard architectural constraints. The assigned IEC 62304 safety class directly dictates the documentation and testing requirements for each independent software item. Furthermore, MDR classification rules demand a clean physical or logical separation between evolutionary machine learning models and the core regulated device.

Post-market surveillance obligations under both UK and EU frameworks require deliberate architectural decisions regarding real-time clinical logging and anomaly detection. Developers must build these diagnostic features into the system from inception rather than attempting to retrofit them later [7].

The practical implication for architectural planning is that regulatory classification must precede component design. A technology leader allocating engineering resources without first resolving whether their product is a Class I or Class IIa device faces compounding rework as the codebase matures. This structural risk is amplified when integrating external Software of Unknown Provenance or dynamic clinical intelligence layers [13].

2. The Architecture Landscape

The architecture decisions facing a healthtech CTO in 2026 are not simply technical. They are regulatory, operational, and commercial all at once. The choice between a monolithic and a microservices architecture carries direct implications under IEC 62304, UK GDPR, and NHS England's digital requirements.

The same applies to the choice between on-premise and cloud-native deployment, and between a specialised integration strategy and a unified platform. This section maps the current state of play. [7] [17]

Cloud-Native and the Microservices Question

Cloud-native architecture has become the default for new healthtech products, driven by the elasticity, scalability, and reduced infrastructure overhead it offers. However, the transition to containerised microservices in healthcare carries specific risks that generic cloud-native guidance does not address [13].

IEC 62304 mandates documented software architecture planning as part of the software development lifecycle. It specifically requires that software items are classified by safety impact and that the architecture supports the required maintenance activities [17].

In a microservices environment, this requirement becomes complex. Each service that contributes to a safety-relevant function must be individually traceable to its requirements, hazard analysis, and verification evidence [7].

Laukkarinen et al. found that reconciling IEC 62304 with continuous integration and continuous delivery pipelines presented significant challenges [7]. Specifically, the phase-gated documentation model of IEC 62304 is structurally misaligned with the iterative delivery model of DevOps.

Their analysis suggests that teams adopting cloud-native microservices for IEC 62304-classified software need to implement additional governance layers to maintain regulatory traceability without sacrificing deployment velocity [13]. Developers can achieve this by automating compliance artefact generation within the deployment pipeline.

For cloud deployment within the NHS context, NHS England's Cloud First policy requires that public sector organisations evaluate cloud solutions before on-premise alternatives. However, NHS England's Data Security and Protection Toolkit (DSPT) imposes specific obligations on where and how patient data can be processed, stored, and transferred. A cloud-native SaMD product targeting NHS procurement must demonstrate DSPT compliance, which is verified through the annual self-assessment process.

To clear the Data Protection Impact Assessment (DPIA) under UK GDPR, containerised environments must enforce strict architectural checkpoints. These controls require zero-trust data access, including mutual TLS between microservices, encryption of data at rest, and granular role-based access controls for service accounts. This configuration ensures that even if one container is compromised, the broader patient data pipeline remains completely isolated and secure.

Data Sovereignty and the UK GDPR Imperative

UK GDPR imposes obligations on the handling of health data that fundamentally constrain architectural choices. Health records constitute special category data under Article 9, requiring an explicit legal basis for processing and additional safeguards for cross-border transfers. The ICO's guidance on international transfers requires that transfers of UK health data to processors or sub-processors outside the UK ensure an adequate level of protection.

This constraint directly affects choices about cloud hosting providers, SaaS dependencies, and multi-region deployment architectures. For NHS-connected systems, NHS England's interim Cloud Computing Policy specifies that health and care data should be hosted within the UK or in approved locations. There are specific conditions for data processed by US cloud providers following the extension of the US CLOUD Act.

The practical consequence for architecture teams is that a product designed for NHS use cannot simply adopt the default multi-region deployment architecture common in consumer SaaS products. Data residency must be explicitly architected from the outset [7]. This requires isolating data persistence layers to designated regional availability zones.

Real-world evidence of enforcement action underscores the stakes. Breach reporting from the ICO shows that healthcare data breaches consistently represent one of the highest-reported sectors for personal data violations. A significant proportion is attributable to cloud misconfiguration and third-party processor failures [10].

The pattern is instructive for systems architects. The attack surface introduced by cloud-native architectures and distributed microservices multiplies the number of potential breach points in the data pipeline [10]. This vulnerability demands automated compliance scanning and regular penetration testing of all microservice endpoints.

FHIR as a Structural Constraint, Not Just an Integration Pattern

FHIR has transitioned from a promising standard to a de facto architectural constraint [6]. The NHS England FHIR Core 1.2.2 implementation defines the data structures and APIs that any product targeting NHS integration must support. This is not merely an integration concern, but a fundamental architectural decision.

Choosing FHIR-native development versus building FHIR translation layers into a legacy-compatible system has significant downstream implications. These decisions dictate your IEC 62304 classification scope, maintainability, and NHS procurement compliance [6].

The FHIR interoperability landscape reveals a consistent finding. FHIR solves syntactic interoperability, but semantic heterogeneity across implementations remains a significant problem [6]. These translation dynamics are explored in detail in cross-platform app development.

Multiple sources across the evidence base identify that even FHIR-compliant systems frequently fail to share semantically consistent clinical data without extensive mapping and validation work [7]. For architecture decisions, this means that FHIR certification alone does not guarantee interoperability. The semantic layer requires as much architectural attention as the syntactic layer [6].

The architecture landscape for medical software in 2026 is characterised by compounding obligations rather than independent constraints. Cloud-native microservices offer operational benefits but introduce IEC 62304 traceability complexity while multiplying the data breach attack surface [7]. Additionally, FHIR provides a necessary but insufficient interoperability foundation [6].

UK GDPR and NHS DSPT together require that data residency, transfer mechanisms, and processor governance are designed into the architecture from first principles. They must not be retrofitted as compliance exercises [17]. For a CTO evaluating architectural options, the non-negotiable starting point is a documented architecture.

This architectural blueprint must trace each safety-relevant software item to its IEC 62304 classification [7]. It must also maintain data residency in accordance with UK GDPR obligations while supporting FHIR-based interoperability as a core design constraint rather than an integration add-on [6]. Ensuring these controls are designed in from the beginning avoids costly remediation during clinical trials or NHS procurement.

3. The Interoperability Challenge

Healthcare data exchange remains one of the most prominent technical and organisational challenges in medical software development. The promise of seamless data sharing between clinical systems is frequently undermined by fragmentation across vendors, standards, and jurisdictions. For a CTO evaluating integration pathways, navigating this landscape is essential to avoid the architectural failures that have historically stalled clinical interoperability initiatives.

To build systems that integrate cleanly with existing clinical infrastructures, organisations must look to established, open-standards frameworks. This is particularly critical when planning complex deployments in the UK, where clinical safety and alignment with NHS systems dictate strict data exchange protocols.

FHIR as the Dominant Standard

The Fast Healthcare Interoperability Resources (FHIR) specification, developed by Health Level Seven International (HL7), has emerged as the principal framework for health data exchange. FHIR was designed specifically to address the fundamental limitations of its predecessors, HL7 v2 and v3, which suffered from rigid message structures and poor implementation consistency across vendors. While a systematic literature review of eighty articles confirms that FHIR has the potential to solve persistent interoperability issues, challenges regarding implementation complexity and adoption rates remain [5].

FHIR's RESTful architecture and resource-based data model represent a deliberate departure from the legacy, document-centric approaches of older standards. By enabling granular access to individual clinical data elements such as patient demographics, observations, and diagnostic reports, FHIR avoids the need to transmit entire clinical documents. This structural granularity supports both human-readable presentation and automated, machine-readable processing across modern web APIs.

The empirical evidence supporting FHIR as a foundation for advanced clinical applications is substantial. Deep learning models trained on FHIR-formatted Electronic Health Record (EHR) data achieved area under the receiver operating characteristic (AUROC) values of 0.93 to 0.94 for predicting in-hospital mortality [1]. This demonstrates that standardising data structures does not compromise analytical accuracy or predictive power.

Furthermore, academic analysis shows that 73% of FHIR research in health studies has focused directly on clinical research applications. Within these studies, data standardisation was cited as the dominant use case at 41% [9]. These figures confirm that the standard has achieved significant practical traction within both research and commercial environments.

EHR Integration Complexity

The reality of EHR integration in active clinical settings diverges sharply from the theoretical promise of FHIR. In major markets, extreme vendor concentration creates downstream interoperability barriers that extend far beyond simple technical compatibility. For instance, six vendors dominate 90% of hospital installations globally, creating natural gatekeeping dynamics that complicate third-party integration efforts [12].

Even when dominant vendors advance interoperability through network initiatives, practitioners consistently describe cross-vendor data exchange as highly problematic. Software developers integrating with proprietary FHIR APIs regularly report persistent difficulties with OAuth 2.0 authentication and inconsistent resource structures across different health systems. These issues are compounded by restrictive write-back permissions in sandbox environments, which limit real-world testing.

An analysis of failed clinical artificial intelligence integrations across health systems found that forty-one out of forty-seven failures occurred because the EHR vendor explicitly blocked third-party access at the API layer [12]. This operational resistance highlights why technical planning must account for business-level vendor cooperation. When transitioning legacy HL7 v2 messaging models into modern FHIR R4 resources, developers must map loose segment structures to strict FHIR resource fields, which often leads to semantic data loss.

Interoperability challenges operate at three distinct levels: syntactic, semantic, and organisational. Systematic reviews of semantic interoperability approaches identify six core methodological categories, including mapping, terminology services, RDF and OWL ontologies, schema annotations, machine learning, and ontology-based systems [5]. Currently, there is no industry consensus on which methodology represents the optimal approach.

This methodological fragmentation reflects the genuine difficulty of achieving meaningful clinical data exchange. Clinical concepts are represented differently across legacy systems, medical specialties, and national jurisdictions. Achieving alignment requires comprehensive terminology translation tables and constant schema verification.

API-First Architecture for Health Data Exchange

An API-first architecture has become the standard paradigm for modern health data exchange. This design pattern mirrors both FHIR's RESTful foundations and the broader architectural transition towards service-oriented integration. The SMART on FHIR framework exemplifies this approach, extending OAuth 2.0-based authentication to clinical applications to establish a standardised authorisation layer directly atop FHIR resources.

However, the practical implementation of API-first architectures reveals significant gaps between official specifications and actual deployment realities. For example, the core FHIR specification lacks a native protocol for concurrency control, which can lead to data overwrite conflicts. Research applying formal modelling to FHIR resource access found that existing detection methods achieve only a 25.5% F1 score for race condition identification, though graph-theoretic models can improve this to 90% [9].

International variations in FHIR implementation add another layer of architectural complexity. Research mapping international openEHR archetypes to FHIR profiles achieved only a 65% mapping reuse across twenty-four archetypes and fifteen profiles spanning seven clinical domains [9]. This level of variation demonstrates that community-driven mapping standardisation is still required to address regional clinical fragmentation.

Implications for Integration Strategy

For a CTO planning a healthtech product, these architectural findings dictate several strategic priorities. First, while FHIR has achieved sufficient market adoption to serve as a core data model, the development team must budget for substantial bespoke mapping and implementation complexity. This is especially true when working within legacy-heavy infrastructures where APIs are poorly documented or non-standard.

Second, technical leads must assess the integration history and API openness of target EHR platforms early in the discovery phase. Finally, while an API-first approach remains the correct architectural decision, teams must build robust middleware to handle authentication variability and concurrency issues.

4. AI/ML in Medical Software

Machine learning forces healthcare software to move beyond deterministic architectures. For instance, data published in JAMA Network Open identified 950 AI or machine learning devices authorised by the FDA as of January 2025, with radiology accounting for 76% of these clearances. These figures demonstrate that while algorithmic diagnostic tools are scaling rapidly, they require rigorous validation to satisfy clinical safety requirements.

Clinical decision support systems represent the primary application of these technologies within modern care environments. The Office of the National Coordinator for Health Information Technology reported that 71% of hospitals had integrated predictive algorithms into their electronic health record systems by 2024. Furthermore, a HIMSS-Medscape survey revealed that 86% of healthcare systems now employ some form of artificial intelligence, primarily targeting diagnostic detection and clinical decision support.

IEC 62304 and the AI/ML Lifecycle Gap

When developing these systems, IEC 62304 serves as the foundational regulatory standard governing software life cycle requirements across major jurisdictions [7]. This framework assigns safety classifications of Class A, Class B, or Class C based on the potential of the system to contribute to hazardous scenarios. Each classification level demands corresponding tiers of technical documentation and rigorous verification processes to ensure patient safety.

However, a structural mismatch exists because IEC 62304 was designed around planned, highly deterministic software engineering methodologies [7]. Clause 4.3 of the standard explicitly excludes machine learning training from the regulated lifecycle, effectively separating algorithm learning from traditional software controls [7]. This exclusion creates significant friction, as engineering teams must reconcile continuous training models with a standard built for static code.

Practising engineers frequently highlight this operational disconnect in technical forums, noting that the sequential development cycles embedded in IEC 62304 do not align with iterative model training [13]. Validating a system becomes exceptionally difficult when model parameters shift during training runs [13]. Consequently, developers report that 90% of compliance delays stem from incomplete technical files, a challenge that is severely amplified when managing adaptive components [13].

FDA AI/ML Guidance and the Predetermined Change Control Plan

To address these dynamic systems, the FDA finalised its predetermined change control plan guidance in December 2024 as part of its broader AI/ML software action plan. This regulatory pathway covers 510(k), De Novo, and Pre-Market Approval routes, allowing engineering teams to gain upfront approval for planned model iterations. By outlining performance boundaries and verification protocols prospectively, manufacturers can update algorithms without triggering repeated, costly premarket submissions.

In a collaborative effort to standardise these practices, the FDA, Health Canada, and the UK MHRA jointly established ten guiding principles for machine learning development in 2021 [17]. These criteria govern data quality, model robustness, transparency, and post-market surveillance to ensure clinical safety [17]. Designing systems in compliance with these principles is essential, and these processes are explored further in AI application development.

Cross-Jurisdictional Alignment: UK/EU Frameworks

Beyond regional rules, the IMDRF SaMD Framework establishes a standardised global approach for categorising medical software risks [17]. The framework evaluates the criticality of the clinical situation alongside the significance of the information provided, producing four distinct risk tiers [17]. This matrix was further refined by January 2025 IMDRF guidance, which updated characterisation considerations for software updates in clinical settings [17].

Within the European Union, the EU MDR 2017/745 imposes demanding classification, clinical evaluation, and post-market surveillance obligations on AI software [7]. Academic analysis highlights that these rules create strict hurdles for demonstrating clinical equivalence and safety [7]. Additionally, researchers have questioned whether existing regulations fully address the risks of model autonomy, potential clinical bias, and algorithmic opacity [7].

Clinical Decision Support Classification

Clinical decision support tools remain subject to specific scrutiny under these clinical frameworks. Retrospective systematic reviews indicate that successful tools must offer actionable recommendations, automatic delivery within the clinical workflow, and tight integration with electronic medical records [8]. However, implementing these features requires addressing data shifts and ensuring that clinical users can interpret how a model reached its output [8].

This requirement for clinical interpretability often conflicts with highly complex, non-linear machine learning models. Over 80% of human-centred evaluation studies rely on post-hoc, model-agnostic explainability methods such as SHAP or Grad-CAM [8]. Unfortunately, these methods have known limitations in representing actual clinical reasoning, and small sample sizes in validation studies frequently restrict their generalisability [8].

Implications for Regulated Development

For a technical lead, these findings show that standard IEC 62304 processes are no longer sufficient to govern machine learning development on their own. Development teams must layer ISO 14971 risk management and prospective change control protocols directly into their engineering pipelines. While managing this overhead is demanding, hybrid agile frameworks like C-Scrum offer a realistic way to balance regulatory compliance with fast-paced engineering cycles [7].

5. Software as a Medical Device (SaMD)

Software as a Medical Device (SaMD) occupies a highly structured regulatory category across major international jurisdictions. The International Medical Device Regulators Forum (IMDRF) established the foundational four-tier risk categorisation framework to harmonise global requirements. This comprehensive medical software development guide outlines how this system directly informs modern regulatory approaches within the United Kingdom and the European Union.

Under this framework, SaMD is classified by mapping the significance of the information provided to the clinical decision against the overall criticality of the patient's state. This intersection yields four distinct risk categories, spanning Roman numerals I through IV, where higher tiers require intensive clinical evaluation. Technical leads can map these pathways early during medical software discovery to establish a clear medical device software development plan.

Within the UK and EU markets, manufacturers must align these IMDRF tiers directly with the classification rules under the UK Medical Devices Regulations 2002 and the EU Medical Device Regulation. Under EU MDR Rule 11, software intended to provide information used to take decisions with diagnostic or therapeutic purposes is classified as Class IIa at a minimum. If those decisions could lead to death or irreversible deterioration, the classification escalates rapidly to Class III or Class IIb.

To mitigate these high-risk classifications, technical architects often design logical separation barriers between clinical decision modules and non-regulated administrative features. Isolating the core clinical algorithm into a standalone software item prevents the surrounding platform from inheriting the highest safety classification. This architectural isolation relies on well-documented APIs and strict data contracts to ensure that regulatory audits remain tightly bounded.

These system boundaries directly dictate the software safety classification under international standards such as IEC 62304. Software items are classified as Class A, B, or C based on their potential to cause harm, which determines the overall rigour of the required technical documentation. Decoupling high-risk clinical calculators from routine reporting features allows engineering teams to optimise their medical device software development process without compromising safety.

Classification Tiers and Risk Matrix

The International Medical Device Regulators Forum (IMDRF) framework evaluates Software as a Medical Device (SaMD) across two distinct axes. These parameters assess the clinical importance of the generated information alongside the critical nature of the target patient condition. This multidimensional evaluation categorises applications into four defined risk tiers, moving from Category I through to Category IV.

Category I software carries the lowest regulatory burden because of its minimal impact on patient outcomes in non-critical scenarios. Conversely, Category IV represents the highest tier, covering applications where corrupted or incorrect clinical data could result in severe harm or death. These critical tools demand exceptionally rigorous regulatory oversight and architectural validation.

The 2014 IMDRF document N12 remains the foundational reference for this risk grouping. This baseline was further refined by the January 2025 IMDRF guidance on characterisation considerations, which integrated specific software risk concepts [17]. These structural updates require technical leads to continuously align their documentation with the evolving international framework.

A 2023 JAMA Network Open study analysing 950 AI/ML devices authorised by the FDA revealed that 76% of these instruments were concentrated solely within radiology. This high concentration has deep implications for firms pursuing healthcare software development in unestablished therapeutic or diagnostic fields. For technical teams, the scarcity of existing predicate devices in novel clinical spaces represents a significant strategic obstacle during the architectural design phase.

Quality Management System Requirements

The standard IEC 62304 establishes the essential lifecycle requirements that underpin custom medical software development and wider medical device systems. It assigns a software safety classification of Class A, B, or C based on how a software item contributes to hazardous situations, with Class C representing the highest risk profile. This classification system integrates directly with ISO 14971, which governs the risk-management process from initial hazard identification to post-market surveillance [17].

Engineering teams often encounter friction during agile medical device software development because traditional standards assume deterministic development processes. Consequently, standard frameworks struggle to accommodate dynamic machine learning components and continuously learning clinical algorithms. Indeed, clause 4.3 of the standard excludes model training from the regulated development lifecycle, isolating clinical model learning from the governed software engineering process [7].

This structural exclusion introduces architectural challenges for healthtech teams building intelligent clinical software. When navigating these regulatory boundaries, the assigned safety class directly dictates the depth of technical documentation and verification required during clinical audits. For instance, Class C components demand granular acceptance criteria, rigorous regression testing, and complete traceability across the codebase [13].

Analysis indicates that up to 90% of regulatory delays during software submissions stem from incomplete or poorly structured technical files [13]. This highlights the substantial operational burden that systematic documentation places on engineering teams who treat compliance as an afterthought rather than a core architectural requirement.

UK and EU Premarket Pathways

Following the United Kingdom's departure from the European Union, manufacturers of Software as a Medical Device (SaMD) must navigate Medicines and Healthcare products Regulatory Agency (MHRA) requirements that align closely with continental principles. The EU Medical Device Regulation (MDR) 2017/745 governs software qualification within the European Economic Area, supplemented by the European Commission's guidance documentation. Under these rules, classification follows Rule 11 and Rule 14 of Annex VIII, which can elevate standalone software to Class III if incorrect output could lead to dangerous clinical inactions [17].

The European pathway requires comprehensive technical documentation demonstrating conformity assessment, robust clinical evaluation reports, and proactive post-market surveillance planning. For software classified as Class IIa and above, the involvement of a third-party Notified Body is a statutory prerequisite. These regulatory guidelines clarify that manufacturers must compile clinical evidence supporting the intended purpose, particularly when evaluating adaptive systems that evolve over their operational lifetime [7].

The European Medicines Agency's recent horizon scanning reports identify continuous learning protocols and ongoing surveillance as pivotal technical concerns for adaptive systems. Manufacturers must implement rigorous change management processes to preserve clinical safety and performance standards during active deployment. Furthermore, the European Artificial Intelligence Act introduces complementary transparency obligations and human oversight measures that intersect directly with existing medical software mandates [8].

Achieving compliance demands the integration of classification-driven risk management, IEC 62304 lifecycle governance, and jurisdiction-specific premarket pathways. The International Medical Device Regulators Forum (IMDRF) framework provides the analytical foundation, whilst ISO 14971 establishes the required risk management protocols. Technical teams often evaluate these pathways during initial product definition to avoid expensive, reactive structural redesigns.

Although the British and European pathways share structural similarities, they diverge in terms of administrative submission routes and certification timelines. While the European framework mandates Notified Body engagement for higher-risk categories, the British regulator maintains distinct processes for conformity assessment. For machine learning models, the exclusion of training cycles from standard software development lifecycles remains a central challenge that teams must resolve to align complex product architectures with regulatory expectations.

6. Build vs Buy: Custom Development vs Commercial EHR Platforms

The build-versus-buy decision in medical software is rarely a straightforward technical choice. It represents a strategic trade-off between differentiation, integration complexity, regulatory exposure, and total cost of ownership. This early-stage decision shapes the entire clinical architecture, vendor relationships, and the long-term regulatory pathway.

For medical software that must interoperate with or replace components of commercial Electronic Health Record (EHR) platforms, the calculus is particularly acute. Building custom solutions allows for precise implementation control. However, this path also introduces significant regulatory compliance burdens that demand careful architectural planning from day one.

When Custom Development Makes Sense

Custom development is warranted when the clinical workflow is highly differentiated. Commercially available platforms cannot deliver these specialised clinical pathways without extensive, costly customisation. Research confirms that proprietary clinical algorithms or machine learning models require bespoke engineering that existing off-the-shelf systems cannot easily accommodate.

The case for building also strengthens when an organisation possesses proprietary clinical data assets that are more efficiently leveraged through tailored tooling. A healthtech company with large volumes of structured clinical data may find that building a specialised AI analytics layer on internal data infrastructure delivers superior results. This approach avoids the limitations of commercial EHR platforms that impose strict API constraints and rigid data formats, as detailed in enterprise app development.

Custom development is also a defensible choice when commercial platforms impose integration constraints that make the target use case practically unachievable. For instance, detailed analyses of Epic's FHIR API integration reveal significant developer friction around authentication, encounter creation, and write-operation limitations in sandbox environments [11]. These technical bottlenecks often force technical leads to bypass commercial sandboxes in favour of custom-built data layers.

Architectural Isolation and SOUP Management

When choosing to build, engineers must carefully isolate Software of Unknown Provenance (SOUP) to prevent classification contamination under IEC 62304. Incorporating third-party libraries or commercial SDKs without strict boundary isolation can cause the high safety classification of those external components to infect the custom software. By establishing robust wrappers and architectural boundaries, teams can run lower-risk custom workflows alongside complex commercial modules.

This decoupling strategy ensures that a failure in a non-critical commercial dependency does not compromise the core clinical safety functions. Isolating SOUP is a critical element of modern software development for regulated environments. It allows teams to optimise their verification scope, keeping regulatory validation costs manageable while maintaining system integrity.

Commercial EHR Platforms and Their Constraints

Epic, EMIS, and TPP SystmOne dominate their respective markets, but each imposes distinct integration constraints that inform the build-versus-buy calculation. Epic operates a massive EHR footprint globally and has been deployed across multiple UK NHS trusts under recent Electronic Patient Record (EPR) tendering frameworks. While its MyChart patient portal and FHIR APIs provide external access to clinical data, the ecosystem remains functionally closed beyond these interfaces.

A 2025 review from KLAS Research found that organisations with strong governance and vendor partnerships reported better EHR implementation outcomes. However, the same report noted that implementations broadly have been a market-wide challenge since the pandemic. A defining constraint of the Epic ecosystem is its historical resistance to external infrastructure, highlighted by its decision to discontinue Google Cloud integrations in 2020.

EMIS and TPP SystmOne represent the dominant general practice platforms within UK primary care. Any healthtech product targeting UK patients at the primary care level must interface with these systems. Unfortunately, EMIS Web requires direct vendor engagement for clinical system configuration, and TPP SystmOne restricts clinical API access behind rigid network and security agreements.

The broader interoperability challenge is well documented. A systematic review by Palojarvi et al. found that semantic interoperability gaps persist even when FHIR is adopted. Ayaz et al. reviewed eighty articles on FHIR and concluded that adoption challenges continue despite the standard's theoretical potential [6].

Cost Thresholds: Custom vs Off-the-Shelf

Total cost of ownership analyses for build-versus-buy decisions must account for direct development costs, regulatory compliance overhead, and ongoing maintenance. For commercial EHR integration work, licensing and integration service costs typically run from tens of thousands to hundreds of thousands of pounds annually. Building equivalent native functionality in-house generally requires engineering teams of three to eight full-time equivalents for an initial build phase of twelve to thirty-six months.

Ongoing maintenance of custom platforms demands a permanent engineering team of at least two to four full-time specialists depending on complexity. Crucially, any health software that falls within the definition of a medical device under EU MDR 2017/745 or the UK MDR 2002 must carry the cost of ISO 13485 Quality Management System implementation [7]. This regulatory floor remains fixed regardless of whether the software is built from scratch or acquired as off-the-shelf and modified.

A practical financial threshold applies. If a commercial platform fulfils eighty percent or more of a clinical workflow requirement with acceptable risk, the build investment required to achieve the remaining twenty percent must be weighed against the QMS overhead. Where the requirement is genuinely novel, such as a specialised analytics pipeline or a unique patient-facing interface, the investment case for custom engineering becomes substantially stronger.

Decision Framework

The build-versus-buy decision for medical software within the EHR ecosystem follows a cascading logic. First, technical leads must determine whether the clinical requirement falls within a regulated device scope. If so, both the build and buy paths require equivalent QMS and regulatory compliance overhead.

Second, engineers must evaluate whether commercial EHR platform APIs and data models can accommodate the requirement without breaching platform terms. If integration constraints are prohibitive or the workflow is highly specialised, custom development becomes the preferred option. However, the IEC 62304 safety classification and associated development process requirements must be funded from the outset.

Finally, for commodity clinical workflow components that are well-served by commercial platforms, buying or integrating is almost always the more cost-effective choice [6]. This decision is ultimately shaped by how much of the clinical value chain an organisation wishes to own versus rent. While platforms like Epic, EMIS, and TPP SystmOne offer the safety of established clinical data management, they impose structural constraints on differentiation, integration scope, and data access that healthtech CTOs must evaluate with complete honesty before committing architectural resources.

7. Vendor and Platform Selection

Selecting an Electronic Health Record (EHR) platform represents a highly consequential technical decision in healthcare software development. Beyond upfront capital requirements, the chosen vendor dictates long-term data portability and determines how easily an organisation can deploy external clinical applications. For healthtech founders operating within the UK NHS or European markets, this selection requires a rigorous, criteria-based framework to avoid vendor lock-in.

A primary evaluation vector is whether a platform is FHIR-native or relies on legacy-integrated translation layers. Systems built on native HL7 FHIR structures allow direct resource querying, whereas legacy databases require complex middleware to map clinical fields. This architectural distinction directly influences the cost and speed of future custom software development efforts.

Technical leads must closely evaluate vendor sandbox environments to understand the real-world behaviour of their integration APIs. Many legacy platforms offer restricted sandboxes that fail to simulate high-concurrency scenarios or state transitions accurately. This discrepancy often leads to integration failures when moving from a simulated testing environment into live clinical workflows.

API authorisation mechanisms also demand close scrutiny, particularly regarding OAuth 2.0 flows and token refresh cycles. Implementations must handle silent token renewals securely within clinical environments without interrupting the end-user's session. Furthermore, write-back capabilities are frequently restricted by vendors, meaning reading patient data is straightforward while writing clinical notes back to the EHR remains highly constrained.

These limitations make upfront testing of write-back endpoints a non-negotiable step in the pre-procurement phase. Engineering teams should document these platform boundaries during an initial medical software discovery phase. Mapping these integration patterns early prevents costly re-engineering when deploying to NHS trusts that rely on distinct EHR instances like Epic, EMIS, or TPP SystmOne.

Evaluation Criteria for EHR Platforms

Robust electronic health record (EHR) platform evaluation requires a structured assessment across clinical, technical, and organisational dimensions. A comprehensive scoping review of 142 studies identified that both positive and negative effects of EHR implementation span clinical workflows, data management, and broader economic impacts [5]. These findings demonstrate that evaluation criteria must extend far beyond simple feature checklists to encompass the complex sociotechnical environment of the clinical space.

The primary barriers to successful adoption typically include resource constraints, inadequate training, and insufficient technical support. Low digital literacy among clinical end users further compounds these operational challenges during live deployment. Identifying these constraints early through a structured medical software discovery phase helps mitigate deployment risks before writing any code.

From a technical standpoint, critical evaluation criteria must focus on API completeness, documentation quality, and strict standards compliance. Engineering teams evaluating epic healthcare software development patterns must test system performance under simulated clinical workloads to assess data integrity mechanisms. Furthermore, the vendor's historical track record with healthcare regulators provides necessary assurance regarding long-term platform stability.

The choice between FHIR-native architectures and legacy-integrated systems warrants meticulous architectural attention from the outset. This engineering decision fundamentally dictates the long-term interoperability posture of the entire healthtech application. Selecting a legacy-integrated system often introduces complex middleware dependencies that degrade system latency and complicate maintenance.

When conducting technical evaluations, engineering teams must rigorously test vendor sandboxes under high-load simulations. This testing should specifically focus on OAuth 2.0 authorisation handshakes, evaluating how the platform handles automated token refreshes during active user sessions. Poorly implemented token refresh flows frequently lead to silent session termination in clinical environments, directly disrupting active patient care.

Another critical evaluation factor is the overall performance and restriction of write-back operations within the sandbox environment. Many legacy EHR platforms restrict write-back capabilities to a limited subset of endpoints, restricting the ability of custom software to update clinical data. Evaluating these write-back constraints early prevents costly architectural workarounds during the later stages of healthcare software development.

FHIR-Native versus Legacy-Integrated Systems

The Fast Healthcare Interoperability Resources (FHIR) standard has established itself as the primary framework for modern healthcare data exchange. However, practitioner accounts reveal substantial disparities between theoretical interoperability and its actual implementation across legacy systems. Healthcare IT professionals note that despite national mandates, individual healthcare systems continue to deploy highly fragmented FHIR Uniform Resource Locator (URL) structures [12].

Applications leveraging the SMART on FHIR profile must configure foreground server authentication protocols uniquely for each vendor environment [12]. The underlying OAuth 2.0 token acquisition workflows exhibit notable inconsistencies between Epic and Cerner environments, which complicates automated client registration. What presents as a unified, standardised specification in regulatory documentation actually demands extensive vendor-specific customisation in practice.

Epic is frequently positioned as an advanced adopter of FHIR interfaces, particularly when operating within broader frameworks such as Carequality [12]. In the context of Epic healthcare software development, even mature ecosystems present cross-vendor data exchange challenges that require significant engineering overhead to resolve schema mismatches [12]. This persistent fragmentation challenges the notion that standardised APIs automatically resolve interoperability hurdles without extensive bespoke adjustments.

Technical leads must rigorously evaluate sandbox environments, testing how each proprietary system handles active session refreshes and write-back limits. Many legacy-integrated systems severely restrict write-back capabilities, forcing engineers to design complex queuing mechanisms to prevent data loss.

For engineering teams, these integration hurdles demonstrate that nominal FHIR compliance claims require active, empirical validation. Rather than relying on static vendor documentation, technical leads should execute early proof-of-concept integrations to uncover hidden endpoint behaviours. Setting a clear architectural baseline during discovery services remains the only reliable way to de-risk high-stakes healthtech deployments.

Data Portability and Vendor Lock-In Concerns

Data portability represents a critical evaluation dimension for organisations that must transition between platforms or enable patients to transfer records across distinct care settings. The US Core Implementation Guide v9.0.0 establishes FHIR profiles for patient demographics, clinical observations, diagnostic reports, medications, and provenance based on FHIR R4. This framework provides an essential foundation for interoperability, supporting scalable data exchange across clinical boundaries.

The Argonaut Project, initiated in 2014, developed foundational specifications for clinical data query and document exchange using OAuth 2.0 security and RESTful API patterns. These industry-standard specifications eventually became the technical basis for the SMART on FHIR standard. This standard directly influences modern healthtech app development by defining how third-party applications securely access clinical databases.

Despite these maturing standards, the practical reality of vendor lock-in persists across the healthcare sector. Organisations evaluating proprietary platforms must carefully assess contract terms regarding data export, proprietary schemas, and raw database ownership. They should also evaluate the completeness of FHIR API implementations against published regional profiles, such as the UK Core or US Core specifications.

Furthermore, technical leads must scrutinise the vendor's historical response to interoperability mandates and API accessibility requests. The distinction between nominal, tick-box FHIR support and comprehensive, tested interoperability remains a significant hurdle during systems integration. Conducting early sandboxed integration testing prevents costly post-deployment architecture re-engineering.

NHS Procurement Context: Platform Considerations

Evaluating digital platforms within the NHS requires a granular understanding of the specific vendor ecosystem and past structural deployments. NHS England's second national Electronic Patient Record (EPR) Usability Survey for secondary care providers offers highly actionable data on how clinicians interact with various systems in practice. These findings underscore the critical importance of usability and workflow alignment when selecting or integrating with external software.

Historical initiatives provide vital context for technical leaders designing modern integrations. Valuable precedents regarding the risk of large-scale national healthcare deployments can be drawn from the National Programme for IT in England, particularly when analysing deployment struggles within mental health settings [2]. These legacy challenges emphasise that centralised architectural decisions must prioritise local clinical workflows to avoid widespread adoption failure.

International initiatives also offer clear structural lessons for technical decision-makers evaluating platform risks. The United States Veterans Affairs (VA) electronic health record modernisation programme serves as a prominent cautionary case study for complex clinical rollouts. Despite localised, incremental enhancements at early deployment sites, a significant fifty-eight per cent of active users raised serious concerns regarding patient safety, system reliability, and clinical workflow disruption.

Such persistent difficulties highlight the long-term architectural risks of rigid, monolithic platform choices. Designated as a high-risk initiative since 2020, the VA programme continues to experience substantial implementation and administrative obstacles. Technical founders must carefully weigh these systemic lessons when assessing whether to integrate with legacy platforms or pursue bespoke medical software discovery pathways to ensure clinical safety and long-term viability.

Recommendations for Technical Decision-Making

Technical leaders evaluating EHR platforms must adopt a structured evaluation framework that prioritises clinical safety and technical interoperability. This rigorous methodology distinguishes between demonstrated API capability and superficial vendor claims.

Proof-of-concept integrations using simulated clinical data samples provide a highly reliable basis for assessing true interoperability. To validate these environments, engineering teams must deploy test instances to evaluate how the target platform handles real-world schema variations.

Assessment teams should specifically examine the consistency and completeness of FHIR resource implementations. They must thoroughly analyse the robustness of authentication flows and the practical engineering effort required to exchange data with external clinical systems.

Platform evaluation must also incorporate long-term structural considerations such as the vendor's financial stability and historical responsiveness to evolving regulatory standards [5]. Furthermore, technical teams should map the openness of the vendor's ecosystem to prevent future dependency lock-in.

The primary goal of EHR platform selection is to establish a secure, extensible foundation that supports complete clinical data portability. This architectural foundation must seamlessly integrate with emerging clinical applications while maintaining operational resilience. Technical teams often initiate this process with a structured medical software discovery phase to map these complex clinical pathways before committing to a platform.

8. The Mobile Question for Clinical Applications

Mobile clinical applications occupy a highly distinct regulatory and technical space within modern healthcare systems. Unlike enterprise electronic health record platforms, mobile applications for clinical environments must reconcile responsive, consumer-grade user experiences with the rigorous safety imperatives of regulated medical devices. These requirements demand an architectural approach that places clinical safety and data integrity ahead of development convenience.

The primary architectural decision for any clinical mobile application centres on whether to pursue native development or cross-platform app development. This structural choice depends heavily on the intended clinical functionality, risk classification under UK MDR 2002, and the target regulatory jurisdiction. The selected framework must support the rigorous verification and validation processes mandated by medical device software standards.

When a mobile application is classified as software as a medical device, the EN 62304 standard applies to its entire development lifecycle regardless of the deployment platform. Developers must document the software architecture down to individual software items to satisfy safety classifications. This process involves proving that third-party code libraries and framework binaries do not introduce unmitigated risks to patients.

Modern cross-platform frameworks have matured significantly, offering highly robust compile-time profiles suitable for clinical use. For instance, Flutter compiles directly to native machine code, avoiding the runtime translation bottlenecks associated with some hybrid approaches. Choosing the right framework is crucial, particularly for regulated systems.

For clinical applications tracking vitals, handling Bluetooth packet loss and raw telemetry data requires rigorous queue management at the bridge layer. Native implementations access platform-specific hardware APIs directly, reducing latency during high-frequency data transmission. In contrast, cross-platform applications must utilise highly optimised native modules to prevent asynchronous thread blocking when verifying critical patient packets.

Remote patient monitoring applications that capture, analyse, and transmit clinical data typically require CE or UKCA marking under European and UK medical device regulations. When these applications determine diagnostic paths or alter therapeutic doses, they fall under Class IIa or higher classifications. This regulatory oversight demands that every mobile release undergoes exhaustive regression testing to prevent clinical hazards.

The FDA guidance on mobile medical applications aligns closely with the European framework, focusing enforcement on software that transforms a mobile platform into a regulated device. Manufacturers must demonstrate that the mobile hardware itself does not compromise the clinical algorithm. Consequently, the software development plan must account for hardware variance across different consumer devices and operating system updates.

Flutter is increasingly used in production NHS environments, proving that modern frameworks can meet strict clinical safety standards. Through careful design and robust testing, engineering teams can deliver compliant mobile applications that streamline healthcare worker workflows.

Mobile architectures must also address strict UK GDPR obligations regarding health data storage, encryption, and transit. Clinical applications must never store unencrypted personal health information on the physical device, utilising secure local enclaves instead. Technical leads planning these structures must understand how to design secure, compliant healthtech tools for the UK clinical landscape.

Native vs Cross-Platform for Clinical Contexts

Native development using Swift and SwiftUI for iOS, or Kotlin and Java for Android, provides deterministic execution and direct hardware access. This direct interaction proves vital when managing real-time telemetry data or resolving Bluetooth packet loss during patient monitoring. Eliminating intermediate bridging layers ensures highly predictable thread scheduling and memory allocation.

For high-acuity environments like bedside monitoring dashboards or diagnostic image viewers, native compilation paths bypass the runtime overhead of cross-platform engines. By keeping the runtime environment simple, engineers can more easily verify system safety and enforce strict execution timelines.

Cross-platform frameworks such as React Native and Flutter reduce upfront engineering costs and accelerate deployment for non-critical healthtech tools. However, when these applications cross into the regulated domain of Software as a Medical Device (SaMD), the structural abstraction layers introduce friction. Opting for cross-platform app development in clinical settings means engineers must map dynamic runtimes to rigorous regulatory requirements, which often complicates compliance workflows.

Under IEC 62304, every software item must be traceably linked from requirements down to the compiled code units [13]. Cross-platform compilation pipelines frequently obscure these underlying implementation details, making it difficult to generate clear traceability reports for external auditors. This technical opacity often inflates the verification burden, offsetting initial speed-to-market advantages.

The IEC 62304 standard defines lifecycle requirements for medical software, assigning safety classifications of Class A, B, or C based on potential clinical harm [17]. Software components built with cross-platform frameworks must be thoroughly documented, and all third-party dependencies are classified as Software of Unknown Provenance (SOUP). This requires engineers to rigorously verify that update cycles in the framework do not compromise core safety functions.

For patient-facing wellness applications or low-risk remote monitoring tools, cross-platform delivery remains a pragmatically sound architectural choice. However, for clinical applications operating at Class B or Class C levels, the engineering hours required to document and test the cross-platform bridge usually exceed the cost of native development. Prioritising native structures from the outset remains a far more predictable path for high-risk clinical healthtech app development deployments.

Regulated Device Requirements: MHRA and FDA Alignment

The MHRA regulates mobile clinical applications under the UK Medical Devices Regulations 2002, which undergoes periodic amendment for alignment with EU MDR. When deploying these regulated products, engineering teams must navigate highly intricate compliance parameters during the software design phase. Manufacturers developing such tools can assess their compliance strategy through structured health tech app development in the UK to ensure conformity to the relevant device class before market placement.

FDA guidance establishes a harmonised international framework for SaMD risk categorisation via IMDRF principles, enabling manufacturers to identify risk categories consistently across jurisdictions [17]. This IMDRF framework classifies software based on the significance of the information provided to clinical decisions and the criticality of the underlying healthcare condition. Ultimately, this matrix defines four distinct risk tiers to categorise the overall potential impact on patient safety and public health [17].

For UK market access, the MHRA applies equivalent classification principles to assess clinical software risk. However, overseas manufacturers must appoint a UK Responsible Person and engage approved bodies for higher-risk device evaluations. This process maintains rigorous safety and performance standards during complex cross-jurisdictional transition periods.

For artificial intelligence in SaMD, the FDA published updated marketing submission guidelines in late 2024 to formalise Predetermined Change Control Plans. This regulatory mechanism allows engineering teams to implement iterative algorithmic improvements under a single initial approval rather than seeking separate submissions for every subsequent update. Additionally, the broader regulatory action plan addresses lifecycle management, real-world clinical performance, and transparent data labelling.

The IEC 62304 standard was originally established to govern planned, highly deterministic clinical software development. Consequently, technical teams frequently observe that the standard struggles to natively accommodate adaptive machine learning systems and continuously evolving neural networks. Specifically, clause 4.3 of the standard excludes model training from the active lifecycle, which effectively segregates algorithmic optimisation from traditional software engineering workflows [7].

The MHRA has mirrored this adaptive approach through its dedicated Software and AI as a Medical Device Change Programme. Although the final statutory framework for continuous learning systems remains in development, interim guidelines offer structural pathways for development teams. Regulators continue to seek a practical balance between rapid, iterative code updates and strict clinical safety validation protocols.

Remote Patient Monitoring: Deployment Considerations

Remote patient monitoring applications present a layered compliance picture. The application itself may or may not qualify as a medical device depending on whether it interprets data or merely transmits it.

A pulse oximetry application that solely displays readings from a connected hardware device falls outside medical classification, whereas an application that applies algorithmic analysis to flag hypoxic events likely qualifies as Software as a Medical Device [17]. Practical considerations for remote health monitoring deployments, including market growth and interoperability challenges, are examined in advancements in remote health monitoring.

Deployments for remote monitoring must also account for rigorous data integrity requirements across the entire transmission chain. Electronic Health Record systems underpinning these workflows must enable the efficient availability of meaningful, accurate, and complete data to support clinical administration [3].

This requirement extends directly to mobile application data handling, which remains a central focus within health tech app development. Clinical mobile applications integrated with legacy databases must maintain absolute data integrity across synchronisation events, which native platforms often address more straightforwardly than cross-platform frameworks.

When transmitting vital signs from peripheral sensors, engineering teams must address Bluetooth packet loss and thread blocking in the mobile application. While native environments allow direct background execution and low-level thread control, cross-platform frameworks can introduce latency during high-frequency data synchronisation. This latency often occurs when the bridge between native device APIs and the shared runtime becomes congested during critical clinical events.

Clinical decision support systems are a prominent application of machine learning in healthcare, with successful implementations characterised by automatic delivery within the clinical workflow [8]. For clinical mobile applications with integrated algorithm features, explainability remains a significant architectural challenge. Over 80% of studies adopt post-hoc model-agnostic approaches despite known limitations, creating a clear gap between technical explainability and clinical reasoning patterns [8].

Recommendations for Architecture Decisions

Selecting an appropriate architectural framework for mobile clinical systems requires a systematic evaluation of regulatory risks and hardware dependencies. When deploying regulated devices in the UK market, engineering teams should default to native development. This path is crucial when the core clinical function involves real-time signal processing, direct hardware sensor integration, or the algorithmic interpretation of patient telemetry.

Conversely, choosing cross-platform app development frameworks remains a highly viable approach for purely informational or administrative functions that do not cross the Software as a Medical Device (SaMD) threshold. Engineering teams must conduct early classification assessments to prevent late-stage regulatory shifts from disrupting the deployment timeline.

Regardless of the chosen mobile framework, all clinical applications must implement software lifecycle documentation compliant with IEC 62304 from the project's inception. Industry consultations regarding SaMD engineering practices indicate that documentation deficiencies, rather than technical execution, represent the primary cause of regulatory delay or failure [13]. Constructing this technical file incrementally during active development sprints reduces systemic project risk and ensures a smoother conformity assessment.

For mobile apps incorporating artificial intelligence, developers must establish robust Predetermined Change Control Plans (PCCPs) during the initial design phase. This proactive planning allows manufacturers to outline future algorithmic modifications and secure pre-submission guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) for continuous learning models. Aligning these architectures with established regulatory pathways ensures the software remains compliant as clinical algorithms iterate over time.

9. How Healthtech Decision-Makers Actually Talk

Healthtech chief technology officers and product founders routinely express profound anxiety regarding the boundary lines of medical device classification. The core source of tension rests on whether proprietary clinical algorithms require UKCA or CE marking, or if they can remain classified as non-device administrative systems. This foundational uncertainty dictates subsequent engineering choices, transforming regulatory strategy into the base layer of healthtech app development in the UK.

When engineering teams transition into regulated territory, the documentation overhead associated with IEC 62304 often causes significant operational friction. Engineering leads regularly report that generating compliant architecture records and software unit verification protocols feels as though it doubles active development timelines. Resolving these requirements early is crucial, often starting with a structured medical software discovery phase to map out exact technical obligations.

Integration with legacy primary care electronic health records, such as EMIS and TPP SystmOne, remains another persistent area of technical dread. Many engineering teams find themselves unprepared for the months of administrative negotiations and legacy messaging paradigms required to achieve live clinical write-back capabilities. Software architects frequently express frustration that promises of universal FHIR interoperability disappear when confronted with proprietary vendor API restrictions.

During the procurement phase, especially within NHS frameworks, the interaction between technical teams and Clinical Safety Officers becomes a critical pathway. Under the DCB0129 and DCB0160 standards, clinical safety hazard logs must directly map to the software architecture documentation created by the engineering team. This collaborative review demands that engineers translate system exception handling, database failovers, and integration boundaries into clear risk mitigations.

Mid-market healthtech firms face a unique dilemma where their scale justifies custom development, yet the compliance overhead of maintaining a certified system feels disproportionate. This struggle is intensified by the regulatory ambiguity surrounding clinical decision support tools and AI components. Founders frequently delay critical product decisions because the boundaries of regulatory enforcement remain difficult to navigate.

The Regulatory-First Frame

When healthtech technical leaders and NHS digital procurement teams evaluate new systems, they start with a fundamental question. Regulatory classification is never treated as a final checklist item; rather, it is the initial step in the software design sequence. This priority dictates every subsequent architectural choice and data management strategy.

Practitioner discussions within the clinical community highlight that experienced engineers begin by establishing whether their work qualifies as a medical device. This assessment measures the platform against the UK MDR 2002, the EU MDR 2017/745, and relevant FDA frameworks. Navigating these requirements early prevents catastrophic missteps before the first line of code is written.

Failing to secure the correct classification before launching healthtech application development in the UK exposes organisations to severe commercial risks. Unauthorised Software as a Medical Device (SaMD) deployments face immediate regulatory enforcement, product recalls, and damaging financial penalties. For emerging software providers, these operational setbacks can permanently halt market access.

Establishing a regulatory-first framework is not merely a risk-mitigation exercise; it acts as a primary commercial gate. Defining the classification early determines the scope of the software architecture, the required documentation protocols, and the post-market clinical surveillance framework. This upfront rigour is essential for building technical trust with NHS commissioners and securing enterprise-level contracts within specialised healthcare procurement systems.

SaMD Classification as Procurement Gateway

The International Medical Device Regulators Forum (IMDRF) risk categorisation framework provides the operative vocabulary for key architectural decisions. This standardised model is adopted across FDA, EU, and UK regulatory pathways to harmonise software classification. Within this framework, Software as a Medical Device (SaMD) is categorised primarily by the significance of the information provided to the clinical decision.

This classification is evaluated against the criticality of the underlying healthcare condition being addressed. This intersection establishes four distinct risk tiers that dictate both the engineering and validation burden [17]. Designing software with these specific tiers in mind ensures that technical teams build only what is required to satisfy safety parameters.

For NHS digital leads evaluating clinical software, this risk framework determines whether a product requires formal CE or UKCA marking under medical device regulations or whether Digital Technology Assessment Criteria (DTAC) compliance is sufficient. Forum evidence confirms that NHS digital procurement teams increasingly request IEC 62304 compliance documentation as a contractual prerequisite. This international standard ensures that the software development lifecycle follows rigorous, documented hazard assessments.

Having this documentation prepared is no longer a simple optional extra for technical founders. It is now a critical commercial prerequisite that must be in place before any NHS procurement or commercial engagement can proceed [13]. Engaging in a structured medical software discovery process early in the engineering phase helps technical teams map these complex obligations systematically.

IEC 62304 as the Non-Negotiable Anchor

Evidence from academic databases confirms that IEC 62304 functions as the critical anchor in healthcare architectural conversations. A cross-database synthesis describes the standard as establishing the essential lifecycle requirements for medical device software development. This is the primary framework that NHS digital leads and healthtech CTOs evaluate when determining whether engineering practices meet the threshold for clinical safety [7].

The practical implication of this standard is direct, requiring technical teams to integrate compliance into their daily development workflows. Rather than merely satisfying internal engineering preferences, formal alignment serves to satisfy rigorous external procurement gatekeepers.

Software architecture documentation, risk management processes, and verification testing records must be treated as critical commercial assets. These comprehensive files ultimately determine whether an organisation can successfully pass assessments to deploy software within the UK health sector.

Practitioner discussions confirm that the substantial documentation burden imposed by IEC 62304 introduces an unexpected compliance cost. Mid-stage companies frequently underestimate this resource investment during their initial planning and scoping phases.

Indeed, practitioner reports indicate that 90% of delays in SaMD product development stem from incomplete documentation rather than underlying technical failures [13]. This reality highlights a persistent structural tension between traditional compliance documentation and agile medical device software development processes [7].

AI/ML as the Emerging Regulatory Friction Point

The regulatory-first orientation of medical software development faces growing strain from the integration of artificial intelligence and machine learning components within clinical systems. This tension is particularly evident when engineering teams attempt to align adaptive models with rigid verification processes within healthtech software development.

Academic research indicates that AI-enabled Software as a Medical Device (SaMD) creates significant regulatory gaps that legacy frameworks fail to address adequately [8]. Specifically, the international standard IEC 62304 was originally architected for deterministic software where inputs produce predictable, repeatable outputs. Its clause 4.3 explicitly excludes machine learning training phases from the formal medical device lifecycle, creating a sharp division between model training and regulated software engineering.

This structural gap introduces considerable friction during software verification and validation activities. Because continuous learning systems adapt their behaviour based on real-world data, maintaining a static technical file becomes mathematically and operationally impossible. To address this, developers must design robust mitigation strategies, such as isolating the AI model from the core regulatory architecture to prevent classification contamination.

Technical leaders are navigating this complexity by exploring modern frameworks like Predetermined Change Control Plans (PCCPs). These plans, which align with joint guiding principles from the FDA, MHRA, and Health Canada, establish pre-approved pathways for model modifications. Implementing PCCPs requires rigorous documentation of automated regression testing pipelines, version control protocols, and real-world model drift metrics.

Practical experience from developer communities shows that healthtech CTOs and NHS digital leads are actively working through the challenge of applying the risk-based framework of IEC 62304 to machine learning assets. Specialist insights into AI application development demonstrate that isolating volatile model components within a well-defined software architecture is essential for safety. This structural isolation ensures that a change in the model does not trigger a complete, expensive recertification of the entire software system.

Evidence from NHS procurement cycles suggests that diagnostic AI and clinical decision support tools face much slower adoption paths than administrative automation tools. Procurement delays are driven primarily by systemic concerns surrounding trust, clinical liability, and evolving regulatory standards [13]. Clinicians and digital safety officers remain cautious of systems where the decision-making logic is not fully transparent.

This caution is justified, as clinical decision support software intended for diagnosis or therapy falls under MDR Rule 11 as a Class IIa device at a minimum. Rule-based systems, by contrast, offer fully auditable logic paths that present clearer liability profiles. When an adaptive clinical tool generates an incorrect recommendation, current UK law does not yet provide a settled answer on whether liability rests with the developer, the healthcare provider, or the clinician.

What This Means for NHS Market Access

NHS market entry requires absolute regulatory clarity. The MHRA software action plan and the ongoing implementation of EU MDR 2017/745 continue to tighten classification criteria. Consequently, post-market surveillance requirements are becoming substantially more stringent.

For healthtech companies seeking to deploy clinical software into NHS trusts, the architectural implications are direct. Commercial procurement conversations almost invariably begin and end with regulatory classification. Furthermore, the technical quality of regulatory documentation serves as the primary evidence NHS digital decision-makers use to evaluate organisational maturity.

Evidence from practitioner forums confirms that NHS digital decision-makers routinely decline to progress vendor conversations past the initial exploratory meeting. This immediate rejection typically occurs if formal classification documentation is either absent or ambiguous. Engineering teams must therefore treat compliance artefacts as core technical deliverables rather than administrative afterthoughts.

Early-stage healthtech companies whose regulatory affairs capabilities lag behind rapid product development find NHS procurement pathways effectively closed. This commercial barrier persists indefinitely until software classification is formally resolved and documented. Engineering heads must align technical milestones with these clinical safety benchmarks to avoid prolonged market entry delays.

The feedback from clinical safety officers and digital transformation managers reveals a procurement culture that is risk-averse by design. This systemic risk aversion remains the defining characteristic of the NHS digital marketplace rather than a temporary hurdle to bypass. Successful deployment relies on aligning technical architecture directly with these strict gatekeeping expectations.

10. Conclusion

Clinical software development demands a shift from feature-first to regulatory-first engineering. Three elements remain non-negotiable: isolating regulated components to manage compliance boundaries, implementing native interoperability via HL7 FHIR, and maintaining continuous verification under IEC 62304. Approaching these requirements late in the lifecycle inevitably triggers costly architectural remediation.

Mitigating these systemic risks requires aligning clinical safety obligations with core engineering practices from the first day of design. This targeted approach establishes a robust compliance framework and clarifies integration pathways prior to any code compilation, ensuring a reliable route to market.

For technical founders and engineering leads seeking to deliver compliant clinical systems, reviewing documented implementations of these architectural principles is a vital next step. Inspecting real-world deployments provides practical blueprints for navigating complex regulatory standards.

Three Non-Negotiables for Medical Software Development

The evidence base examined across eight research phases converges on three core findings. These phases span SaMD regulatory frameworks, EHR system implementation, AI/ML integration, and practitioner forum perspectives. Technical leadership must treat these three elements as non-negotiable from project inception.

Non-Negotiable 1: Regulatory Architecture Must Precede Code

IEC 62304 is not an administrative exercise to be completed after development. Instead, it serves as a software lifecycle framework that dictates how architectural decisions must be made. For organisations embarking on this path, starting with a structured medical software discovery process ensures compliance is integrated into the core architecture.

The research shows that IEC 62304 assigns software safety classifications of Class A, B, or C based on a component's contribution to hazardous situations. These classifications directly determine the level of rigour required for documentation, testing, and verification throughout the lifecycle [7].

Practitioner forum evidence indicates that up to 90 percent of delays in medical software submissions stem from documentation gaps. These gaps are typically those that should have been addressed during architectural planning rather than retrofitted during submission preparation [13].

The standard embeds a specific software development lifecycle that does not accommodate post-hoc compliance. Organisations that treat regulatory requirements as an architectural first principle achieve more predictable timelines and lower rework costs.

For CTOs, allocating senior engineering time to architecture documentation is one of the clearest investments a project can make. This allocation must remain proportional to the software safety classification, as Class C software requires highly rigorous architectural controls and acceptance criteria [13]. These controls are vital because Class C components can contribute to hazardous situations resulting in death or serious injury.

Non-Negotiable 2: Interoperability Is an Architectural Concern, Not an Integration Detail

Electronic health record implementation research demonstrates that interoperability failures represent the central unresolved challenge across national and institutional systems. This systemic problem operates simultaneously at multiple levels, including syntactic data formats, semantic meanings of clinical terms, and organisational data sharing policies.

Fast Healthcare Interoperability Resources, or FHIR, is widely cited as a promising solution for syntactic interoperability. However, implementation challenges persist, and semantic interoperability gaps remain even when FHIR is adopted [6].

Large-scale national implementations provide cautionary evidence. For instance, England's national electronic health record programme cost over 24 billion pounds before being dismantled, failing in part due to insufficient attention to interoperability at the architectural stage.

Decentralised, federated approaches with national standards emerge from the evidence as more successful. This contrast is sharpest when compared to macro-level, centralised implementations that treat interoperability as an integration problem rather than an architectural foundation [6].

For CTOs, interoperability must be treated as a primary architectural concern that shapes system boundaries, data models, and interface specifications from the outset. It is not a property to be added by integration middleware after core systems are designed.

Non-Negotiable 3: AI/ML Integration Requires Explicit Regulatory Framing

AI and machine learning enabled SaMD creates regulatory gaps that existing frameworks do not fully address. IEC 62304 was designed for planned, deterministic software development and explicitly excludes machine learning training from the regulated software engineering lifecycle [7].

This exclusion effectively segregates AI learning from the regulated development process. To bridge this, the US Food and Drug Administration has introduced Predetermined Change Control Plans, which enable manufacturers to plan predetermined changes upfront.

These plans avoid the need for separate approvals for iterative improvements. However, practitioner forum evidence indicates that debate continues over whether these frameworks adequately address the challenges of validation when models change during training [13].

Research across multiple jurisdictions reveals that regulatory frameworks for artificial intelligence in SaMD remain in active development. The EU MDR and the AI Act create additional obligations for devices placing in European markets, while the FDA's December 2024 final guidance on Predetermined Change Control Plans represents the current regulatory frontier for US market access. Arch's engineering team supports healthtech companies navigating these complex regulatory gaps through specialised healthcare software development solutions.

For CTOs, the implication is clear. AI and machine learning components in medical software require explicit regulatory framing at project initiation.

This framing must include well-defined change management protocols and predetermined change control plans submitted to regulators before deployment. The assumption that standard software development lifecycles accommodate AI components without modification is not supported by the evidence.

To successfully deliver highly regulated clinical tools, engineering leaders must balance rigorous compliance with robust technical execution. Designing these platforms correctly from the ground up protects both patient safety and long-term commercial viability.

A Decision Framework for Technical Leadership

Software architecture in healthcare is dictated by clinical safety requirements. Evaluating medical software development investments requires technical leaders to adopt a pragmatic decision framework. By addressing regulatory demands at the foundational level, engineering teams can navigate compliance complexity without sacrificing velocity.

First, engineering teams must classify before architecting. Software safety classification under IEC 62304 dictates all subsequent architectural choices and documentation requirements. Technical leaders should secure formal regulatory guidance on software classification before detailed design begins.

Second, development teams must design for interoperability by default. Fast Healthcare Interoperability Resources (FHIR) standards and federated data sharing patterns should inform architectural decisions from the earliest design phases. Treating interoperability as a core capability prevents costly retrofitting when integrating with primary care networks.

Third, engineers must frame clinical decision support and machine learning components explicitly. The regulatory pathway for each system must be fully documented, including change management protocols and allowable adaptation ranges. This practice ensures alignment with evolving international guidelines and domestic UK MDR requirements.

The current evidence base reflects a regulatory landscape in active transition. Modern frameworks, technical standards, and engineering practices are all evolving in parallel. These shifts respond to algorithmic capabilities that often outpace legacy compliance requirements.

Technical decision-makers who structure their practices around these three principles are better prepared to adapt as frameworks mature. This proactive posture yields highly predictable outcomes during regulatory audits. Ultimately, systematic early-stage planning reduces the engineering rework that often stalls ambitious healthtech programmes.

Engineering teams that combine clinical compliance knowledge with technical depth produce resilient platforms that align with NHS digital standards and international regulations. This structural alignment allows organisations to confidently navigate complex pathways such as software as a medical device development. Partnering with a specialist team early through a structured discovery process ensures that these architectural foundations are secure from day one.

Ready to Explore Your Medical Software Options?

Whether your engineering team is evaluating commercial EHR platforms, assessing SaMD classification, or planning custom medical software development, Arch works with healthtech organisations at the intersection of regulatory compliance and technical execution. These foundational engineering decisions establish the framework for clinical safety and long-term system viability from day one.

Our structured medical software discovery process helps technical decision-makers map clinical requirements against regulatory pathways and interoperability constraints. By evaluating these critical factors during the initial scoping phases, founders can navigate complex build-versus-buy economics with clear empirical guidance.

We work alongside technical teams to translate rigorous regulatory compliance standards directly into scalable, clean software architectures. This collaborative methodology ensures your clinical product remains both regulatory-compliant and technically resilient from the very first line of code.

View case studies

Frequently Asked Questions

When does medical software require MDR certification?

Software processing patient data to inform clinical decisions generally requires medical device certification under UK MDR 2002 or EU MDR 2017/745. The Software as a Medical Device (SaMD) classification framework determines the exact risk tier and regulatory pathway. Higher-risk categories demand a full quality management system, extensive clinical evidence, and formal premarket review.

What does IEC 62304 compliance require?

IEC 62304 assigns software safety classifications based on the potential to cause physical harm. Class C software, which can contribute to serious injury or death, demands exhaustive documentation and rigorous lifecycle traceability. This classification directly dictates the overall engineering verification and documentation burden during healthcare software development.

How does FHIR affect medical software architecture?

HL7 FHIR serves as the primary interoperability standard for modern health data exchange across NHS networks. However, semantic gaps often persist even when syntactic compliance is met, meaning FHIR adoption alone does not resolve complex integration challenges. Designing FHIR-native architectures from the outset provides far greater stability than attempting to retroactively fit an integration layer.

What is the build-versus-buy decision for EHR integration?

This decision follows a cascading logical pathway that starts by determining whether clinical requirements fall within a regulated device scope. Teams must then evaluate commercial API compatibility before assessing if the workflow warrants custom engineering. Where existing platforms fulfil most requirements, manufacturers must weigh the bespoke development overhead against long-term regulatory maintenance.

How should AI/ML components be handled in medical software?

AI and machine learning components require explicit regulatory framing at project initiation to address structural gaps in standards like IEC 62304. Teams should leverage frameworks like FDA Predetermined Change Control Plans alongside MHRA guidance to structure change management. Defining these validation pathways and allowable adaptation ranges must occur before writing any production code for AI software solutions.

How does the EU MDR 2017/745 classify clinical decision support software?

Under EU MDR Rule 11, software that processes data to support or inform clinical decisions is classified as Class IIa minimum. This classification encompasses algorithms, neural networks, and rule-based systems. It can rise to Class IIb or III if the decisions directly influence patient management in a manner that poses a serious danger to health.

What is the fundamental tension between IEC 62304 and machine learning development?

IEC 62304 was designed for planned, deterministic software development. However, Clause 4.3 of the standard explicitly excludes machine learning training from the regulated software development lifecycle. This exclusion creates a structural gap by segregating active learning from the governed software engineering process.

What are the three non-negotiables for medical software development?

First, regulatory architecture must precede code because safety classifications drive all subsequent design and documentation requirements. Second, interoperability must be treated as an architectural foundation rather than an integration detail. Finally, AI and machine learning components require explicit regulatory framing at the very initiation of the project.

Why does FHIR compliance not automatically guarantee complete system interoperability?

While FHIR successfully addresses syntactic interoperability, semantic heterogeneity across different implementations remains a major problem. Consequently, even FHIR-compliant systems frequently fail to share semantically consistent clinical data. To resolve this, developers must perform extensive mapping and validation work across heterogeneous vendor systems.

About the Author

Hamish Kerry is Marketing Manager at Arch, where he has spent six years shaping how digital products are positioned, launched, and understood. With over eight years of experience in the technology sector, he brings a deep understanding of accessible design and user-centred development to healthtech initiatives.

His insights span AI, mobile application development, and the strategic potential of emerging healthcare technologies. He is particularly focused on helping technical decision-makers navigate the regulatory and architectural challenges of modern software engineering.

References

[1] Sutton RT, Pincock D, Baumgart DC, Sadowski D, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. npj Digital Medicine. 2020. https://doi.org/10.1038/s41746-020-0221-y

[2] Rajkomar A, Oren E, Chen K, et al. Scalable and accurate deep learning with electronic health records. npj Digital Medicine. 2018. https://doi.org/10.1038/s41746-018-0029-1

[3] Miotto R, Wang F, Wang S, Jiang X, Dudley JT. Deep learning for healthcare: review, opportunities and challenges. Briefings in Bioinformatics. 2017. https://doi.org/10.1093/bib/bbx044

[4] Black A, Car J, Pagliari C, et al. The impact of eHealth on the quality and safety of health care: a systematic overview. PLOS Medicine. 2011. https://doi.org/10.1371/journal.pmed.1000387

[5] Johnson AEW, Bulgarelli L, Shen L, et al. MIMIC-IV, a freely accessible electronic health record dataset. Scientific Data. 2023. https://doi.org/10.1038/s41597-022-01899-x

[6] Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implementation Science. 2009. https://doi.org/10.1186/1748-5908-4-50

[7] Williams P, Woodward A. Cybersecurity vulnerabilities in medical devices: a complex environment and multifaceted problem. Medical Devices Evidence and Research. 2015. https://doi.org/10.2147/mder.s50048

[8] Larson DB, Harvey H, Rubin DL, Irani N, Tse JR, Langlotz CP. Regulatory Frameworks for Development and Evaluation of Artificial Intelligence-Based Diagnostic Imaging Algorithms. Journal of the American College of Radiology. 2020. https://doi.org/10.1016/j.jacr.2020.09.060

[9] de Hond A, Leeuwenberg A, Hooft L, et al. Guidelines and quality criteria for artificial intelligence-based prediction models in healthcare: a scoping review. npj Digital Medicine. 2022. https://doi.org/10.1038/s41746-021-00549-7

[10] Memon M, Wagner S, Pedersen CF, Aysha Beevi FHA, Hansen FT. Ambient Assisted Living Healthcare Frameworks, Platforms, Standards, and Quality Attributes. Sensors. 2014. https://doi.org/10.3390/s140304312

[11] Guo C, Ashrafian H, Ghafur S, Fontana G, Gardner C, Prime M. Challenges for the evaluation of digital health solutions: a call for innovative evidence generation approaches. npj Digital Medicine. 2020. https://doi.org/10.1038/s41746-020-00314-2

[12] FDA. Software as a Medical Device (SaMD): FDA Overview. 2018. https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd

[13] FDA. Global Approach to Software as a Medical Device. 2022. https://www.fda.gov/medical-devices/software-medical-device-samd/global-approach-software-medical-device

[14] FDA. Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device Action Plan. 2021. https://www.fda.gov/media/145022/download

[15] NIST. Artificial Intelligence Risk Management Framework (AI RMF 1.0): Generative Artificial Intelligence Profile. 2024. https://nvlpubs.nist.gov/nistpubs/ai/NIST.AI.600-1.pdf

[16] WHO. Ethics and Governance of Artificial Intelligence for Health: Guidance on Large Multi-Modal Models. 2024. https://www.who.int/publications/i/item/9789240084759

These reference sources provide the technical and regulatory foundation for modern healthcare systems. They offer the empirical evidence necessary to navigate complex regulatory pathways and architectural decisions safely.